MENU

Anti-CD22 CAR T-cells: Functional characterization of 24A7G6 and 29H9C8 clones

PloS one Thailand
Overview
Researchers developed novel anti-CD22 CAR T-cells using monoclonal antibody clones 24A7G6 and 29H9C8 to address CD19-negative relapse in B-cell malignancies. In vitro tests showed that the 24A7G6-CD28 construct provided enhanced sustained tumor control compared to 4-1BB versions. These findings establish a basis for prioritizing lead constructs for further preclinical evaluation.
In Depth

Key Findings

The study successfully generated and characterized novel anti-CD22 chimeric antigen receptor (CAR) T-cells derived from newly developed monoclonal antibody clones. Among four screened clones, 24A7G6 and 29H9C8 were selected for CAR development due to their favorable binding and surface expression profiles. Both clones mediated potent antigen-specific cytotoxicity against CD22-positive Raji and Nalm-6 cells, while showing no activity against CD22-negative K562 cells.

Technical Details

The researchers developed second-generation CAR constructs incorporating either a 4-1BB or CD28 costimulatory domain, which were then introduced into primary human T cells. The resulting CAR T-cells were evaluated across several metrics:

  • Phenotype: CAR T-cells expanded efficiently and showed predominant CD8+ populations with naïve and central memory phenotypes.
  • Activation: Following antigen stimulation, the cells upregulated activation markers and showed modest increases in inhibitory receptors.
  • Persistence: In long-term co-culture and sequential tumor rechallenge assays, all constructs maintained antitumor activity under prolonged antigen exposure.
  • Comparative Performance: While short-term cytotoxicity was comparable across constructs, the 24A7G6-CD28 CAR demonstrated superior sustained tumor control compared to the 24A7G6-4-1BB construct in extended assays.

Background and Context

CD19-directed CAR T-cell therapies have achieved complete remission rates exceeding 80–90% in patients with relapsed or refractory B-ALL. However, disease relapse often occurs due to “antigen escape,” where tumor cells downregulate or eliminate CD19 expression through point mutations, alternative splicing, or lineage switching. CD22 is a transmembrane sialoglycoprotein of the Siglec family that remains expressed on malignant B cells even after CD19-directed therapy, making it a viable alternative target.

Significance and Outlook

By comparing distinct scFv frameworks and costimulatory domains, this research optimizes the functionality and persistence of CD22-targeted CAR T-cells. The identification of 24A7G6 and 29H9C8 as effective targeting domains provides the necessary in vitro evidence to prioritize these lead constructs for subsequent preclinical evaluation.

Source: https://doi.org/10.1371/journal.pone.0362221

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

  • Your email and selected fields are used only to deliver the newsletter.
  • We never share your information with third parties.
  • You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Takes about a minute · Unsubscribe anytime

Published by Troy-Technical, an independent site run by one engineer with a career in materials development.
About the author / Contact info@troy-technical.jp
Let's share this post !

Author of this article

TOC